Aardvark Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-57.6M | $-20.6M |
| Depreciation & Amortization | $36.0K | $16.0K |
| Depreciation | — | — |
| Amortization | — | — |
| Stock-Based Compensation | $3.9M | $439.0K |
| Net Cash from Operating Activities | $-54.2M | $-18.1M |
| Investing Activities | ||
| Capital Expenditures | $95.0K | $109.0K |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-49.7M | $-12.0M |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $89.2M | $82.0M |
| Net Change in Cash | — | — |
| Free Cash Flow | $-54.3M | $-18.2M |